This is a routine shareholder meeting with no material financial impact. Monitor for any unexpected outcomes in the director elections or auditor ratification.
BIOA drugs
BIOA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 22 $18.36entry
- T+1 · 7mo ago −6.10%α −5.71% · $17.24
- T+5 · 7mo ago −6.64%α −6.70% · $17.14
- T+20 · 6mo ago −10.84%α −14.00% · $16.37
- T+60 · 4mo ago +24.24%α +19.46% · $22.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioAge Labs, Inc. is holding its 2026 annual meeting to elect three Class II directors and ratify the appointment of KPMG LLP as its independent registered public accounting firm. The board recommends voting FOR both proposals.
Key Financial Metrics
Key Facts
- BioAge Labs, Inc. is holding its 2026 annual meeting on June 10, 2026.
- The meeting will be held virtually via the internet.
- Shareholders of record as of April 16, 2026 are eligible to vote.
- Proposal 1 is to elect three Class II directors: Patrick Enright, James I. Healy, and Rekha Hemrajani.
- Proposal 2 is to ratify the appointment of KPMG LLP as the independent registered public accounting firm for 2026.
- The board of directors recommends voting FOR both proposals.
- The company has recently seen insider selling of $157K.
Financial Impact
Routine corporate governance matters with no immediate financial impact.
Risk Factors
- Potential for shareholder dissent on director elections.
- Risk of auditor change if KPMG is not ratified.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-166751 |
| Document: 0001193125-26-166751-index-headers.html | 0001193125-26-166751 |
| Document: 0001193125-26-166751-index.html | 0001193125-26-166751 |
| Document: 0001193125-26-166751.txt | 0001193125-26-166751 |
Track record
11 reports on BIOA
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
- Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
- May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Viewing Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
- Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
- Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
- Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
- Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers